Govea-Alonso Dania O, Malla Ashwini, Bolaños-Martínez Omayra C, Vimolmangkang Sornkanok, Rosales-Mendoza Sergio
Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosi 78210, Mexico.
Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona 550, Lomas 2ª Sección, San Luis Potosi 78210, Mexico.
Pharmaceuticals (Basel). 2022 Oct 21;15(10):1298. doi: 10.3390/ph15101298.
Despite the current advances in global vaccination against SARS-CoV-2, boosting is still required to sustain immunity in the population, and the induction of sterilizing immunity remains as a pending goal. Low-cost oral immunogens could be used as the basis for the design of affordable and easy-to-administer booster vaccines. Algae stand as promising platforms to produce immunogens at low cost, and it is possible to use them as oral delivery carriers since they are edible (not requiring complex purification and formulation processes). Herein, a -made SARS-CoV-2 RBD was evaluated as an oral immunogen in mice to explore the feasibility of developing an oral algae-based vaccine. The test immunogen was stable in freeze-dried algae biomass and able to induce, by the oral route, systemic and mucosal humoral responses against the spike protein at a similar magnitude to those induced by injected antigen plus alum adjuvant. IgG subclass analysis revealed a Th2-bias response which lasted over 4 months after the last immunization. The induced antibodies showed a similar reactivity against either Delta or Omicron variants. This study represents a step forward in the development of oral vaccines that could accelerate massive immunization.
尽管目前全球针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗接种取得了进展,但仍需要加强免疫以维持人群免疫力,而诱导无菌免疫仍是一个有待实现的目标。低成本口服免疫原可作为设计经济实惠且易于给药的加强疫苗的基础。藻类是有望低成本生产免疫原的平台,并且由于它们可食用(不需要复杂的纯化和制剂工艺),因此有可能将它们用作口服递送载体。在此,对一种人工合成的SARS-CoV-2受体结合域(RBD)作为小鼠口服免疫原进行了评估,以探索开发基于藻类的口服疫苗的可行性。测试免疫原在冻干的藻类生物质中稳定,并且通过口服途径能够诱导针对刺突蛋白的全身性和黏膜体液反应,其程度与注射抗原加明矾佐剂诱导的反应相似。IgG亚类分析显示为Th2偏向性反应,在最后一次免疫后持续超过4个月。诱导产生的抗体对德尔塔或奥密克戎变体显示出相似的反应性。这项研究代表了口服疫苗开发的一个进步,有望加速大规模免疫接种。